NRX PHARMACEUTICALS INC
NASDAQ: NRXP (NRX Pharmaceuticals, Inc.)
Last update: 2 hours ago3.13
-0.13 (-3.99%)
| Previous Close | 3.26 |
| Open | 3.25 |
| Volume | 185,167 |
| Avg. Volume (3M) | 261,995 |
| Market Cap | 61,045,644 |
| Price / Book | 2.90 |
| 52 Weeks Range | |
| Earnings Date | 12 Aug 2025 - 18 Aug 2025 |
| Diluted EPS (TTM) | -1.96 |
| Current Ratio (MRQ) | 0.220 |
| Operating Cash Flow (TTM) | -10.45 M |
| Levered Free Cash Flow (TTM) | 3.23 M |
| Return on Assets (TTM) | -191.74% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | NRX Pharmaceuticals, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.5 |
| Average | 1.38 |
|
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 15.88% |
| % Held by Institutions | 13.08% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Anson Funds Management Lp | 31 Mar 2025 | 1,179,061 |
| Advisorshares Investments Llc | 31 Mar 2025 | 286,797 |
| Townsquare Capital Llc | 31 Mar 2025 | 15,041 |
| One Wealth Management Investment & Advisory Services, Llc | 31 Mar 2025 | 15,041 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 46.00 (Ascendiant Capital, 1,369.65%) | Buy |
| Median | 31.00 (890.42%) | |
| Low | 18.00 (BTIG, 475.08%) | Buy |
| Average | 31.67 (911.82%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 2.39 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| D. Boral Capital | 23 Jun 2025 | 31.00 (890.42%) | Buy | 3.10 |
| 20 Jun 2025 | 31.00 (890.42%) | Buy | 3.26 | |
| Ascendiant Capital | 29 Apr 2025 | 46.00 (1,369.65%) | Buy | 2.06 |
| BTIG | 02 Apr 2025 | 18.00 (475.08%) | Buy | 2.01 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |